LONDON, UK. JANUARY 2018: Visiongain has launched a new pharma report Global Ortho and Osteobiologics Market 2018-2028: Viscosupplementation Products, Demineralized Bone Matrices, Synthetic Orthobiologics, Bone Morphogenic Protein, Allografts, Plasma-rich Protein, Bone Marrow Aspirate, Osteoarthritis, Spinal Fusion, Fracture, Soft Tissue Injury, Hospitals, Clinics, Research and Academic Institutes
The Ortho and Osteobiologics industry has evolved tremendously in recent years with an array of novel technological development being designated to treat orthopaedic disorders. The regulatory authorities such as the U.S. FDA and EMA are streamlining the regulatory process and approving different advanced devices. There is a huge market potential in the developing countries of Asia-Pacific and LAMEA regions, as the healthcare infrastructure, awareness, and affordability have increased in these regions.
The lead analyst of the report commented “Continuous technological innovations in ortho and osteobiologics industry is set to drive the market at an exponential rate. The emergence of natural biomaterials-based ortho and osteobiologics has revolutionized the ortho and osteobiologics industry as these have several advantages compared to synthetic biomaterials.
Competitive rivalry is intense in the Ortho and Osteobiologics market owing to high number of competitors of nearly equal market size and share. Companies competing in the Ortho and Osteobiologics market are continuously putting efforts to gain market share through novel product launches & product approvals owing to the large scope of product differentiation.”
Leading companies featured in the report include Johnson & Johnson (DePuy Synthes), Medtronic PLC, Colson Associates, Inc. (OsteoMed LLC), Arthrex, Inc, Stryker Corporation, Zimmer Biomet Holdings, Inc. (Zimmer Biomet), Smith & Nephew plc, Orthofix International N.V., Skye Osteobiologics Inc., BioVentus.
Notes for Editors